For example, in patients with acute myeloid leukemia (AML), an accumulation of unconventional CD56− CD16+ NK cells, probably as a consequence of immune escape from innate immunity during AML progression, correlated with worse prognosis [56], thus suggesting the use of these molecules as prognostic markers. This evidence concerns the gene NCAM1 and acute myeloid leukemia.